Business Context and Reporting Period
Company: SELLAS Life Sciences Group, Inc. (SLS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapeutics. Its pipeline consists of two primary candidates: galinpepimut-S (GPS), a peptide immunotherapy targeting the WT1 antigen, and SLS009 (tambiciclib), a selective CDK9 inhibitor. The company has no approved products and currently generates no product revenue.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Research & Development Expenses | $16,022 | $19,096 |
| General & Administrative Expenses | $12,252 | $12,417 |
| Net Loss | $(26,863) | $(30,881) |
| Cash and Cash Equivalents (Year End) | $71,793 | $13,886 |
| Accumulated Deficit | $(274,988) | $(248,125) |
| Net Cash Used in Operating Activities | $(28,389) | $(35,402) |
| Net Cash Provided by Financing Activities | $86,296 | $46,758 |
Note: The company has no debt obligations listed in the balance sheet liabilities section as of December 31, 2025.
Material Changes vs. Prior Period
- Reduced Operating Loss: Net loss decreased by approximately $4.0 million (13%) compared to 2024, driven primarily by a $3.1 million reduction in R&D expenses.
- R&D Expense Decline: R&D costs dropped from $19.1 million to $16.0 million. This was largely due to the completion of enrollment in the Phase 3 REGAL study for GPS and the Phase 2a trial for SLS009, reducing external clinical trial costs by $3.4 million combined.
- Significant Liquidity Improvement: Cash and cash equivalents increased from $13.9 million to $71.8 million. This surge was fueled by $86.3 million in net financing proceeds, including registered direct offerings and warrant inducement agreements in 2025.
- Stock-Based Compensation: Total stock-based compensation increased to $2.0 million in 2025 from $1.6 million in 2024.
Guidance, Outlook, and Risks
Clinical Development Outlook
- GPS (Galinpepimut-S): The pivotal Phase 3 REGAL study in AML patients is ongoing. Enrollment was completed in March 2024. As of December 26, 2025, 72 of the required 80 events (deaths) for the final analysis had occurred. The company remains blinded to efficacy data. A Biologics License Application (BLA) is expected to be filed upon successful completion of the final analysis.
- SLS009 (Tambiciclib): The Phase 2a trial in relapsed/refractory AML met all primary endpoints in July 2025, showing an overall response rate of 33% and median overall survival of 8.8–8.9 months (surpassing the historical benchmark of ~2.4 months). The FDA recommended advancing to a first-line Phase 2 trial, which began enrollment in Q1 2026.
Management Commentary & Liquidity
Management expects current cash resources, combined with $42.6 million in warrant exercise proceeds received subsequent to December 31, 2025, to fund operations for at least the next 12 months. However, the company anticipates continuing to incur substantial losses and will require additional financing to complete development and commercialization.
Key Risks and Contingencies
- Arbitration with 3D Medicines: The company is engaged in binding arbitration against its Greater China licensee, 3D Medicines, regarding milestone payments and development diligence. $191.5 million in potential future milestones remains under this agreement but is contingent on variable events.
- Capital Requirements: Continued reliance on equity financing may result in significant dilution to existing shareholders.
- Regulatory Uncertainty: No products are approved; success depends on positive clinical trial outcomes and regulatory approvals from the FDA and EMA.
- Manufacturing Dependence: The company relies entirely on third-party contract manufacturers for GPS and SLS009.
Investor Verification Checklist
- REGAL Study Timeline: Verify the date of the 80th event (death) in the GPS Phase 3 trial, as this triggers the final data readout and potential BLA filing.
- Arbitration Status: Monitor updates on the arbitration proceeding against 3D Medicines, as a resolution could impact future milestone revenue recognition.
- Cash Burn Rate: Confirm the company's ability to extend its cash runway beyond the 12-month horizon given the high costs of late-stage clinical trials.
- SLS009 First-Line Trial: Track enrollment progress and interim data from the new first-line AML Phase 2 trial initiated in Q1 2026.
- Warrant Exercises: Review subsequent filings for additional warrant exercises to assess ongoing capital support and potential dilution.